Cullinan Therapeutics Receives Approval to Initiate its Global Phase 1 Clinical Trial of CLN-978 for the Treatment of Systemic Lupus Erythematosus

Rhea-AI Summary

Cullinan Therapeutics (Nasdaq: CGEM) has received approval from the Human Research Ethics Committee (HREC) in Australia to initiate its global Phase 1 clinical trial for CLN-978, a CD19xCD3 bispecific T cell engager, in treating systemic lupus erythematosus (SLE). The trial will assess safety, pharmacokinetics, and initial clinical activity of CLN-978 in SLE patients, which affects approximately 430,000 individuals globally. The study will be conducted across multiple sites in Australia and other countries worldwide.

CLN-978 is designed to deliver T cell-directed potency with off-the-shelf access and convenient dosing, potentially offering a best-in-class treatment for SLE. This approval marks a significant step in Cullinan's global clinical development strategy for autoimmune diseases. The company has also submitted an Investigational New Drug Application to the U.S. FDA for this study.

Positive

• Received HREC approval in Australia to initiate global Phase 1 clinical trial for CLN-978
• CLN-978 targets CD19, potentially offering a best-in-class treatment for SLE
• Submitted Investigational New Drug Application to the U.S. FDA for the study

Negative

• None.

Medical Research Analyst

The approval to initiate a global Phase 1 clinical trial for CLN-978 in systemic lupus erythematosus (SLE) is a significant milestone for Cullinan Therapeutics. This novel CD19xCD3 bispecific T cell engager represents a potentially groundbreaking approach to SLE treatment. Current therapies for SLE, which affects 430,000 people globally, are largely focused on symptom management rather than disease modification.

The trial's design to assess safety, pharmacokinetics and initial clinical activity is important for establishing CLN-978's potential. If successful, it could offer a paradigm shift in SLE treatment, potentially providing treatment-free remission - a major unmet need in the field. The global nature of the trial, starting in Australia with plans to expand worldwide, suggests a comprehensive approach to drug development and could expedite the path to market if results are positive.

Biotech Industry Expert

Cullinan Therapeutics' progress with CLN-978 positions them well in the competitive autoimmune disease market. The company's strategy of developing modality-agnostic targeted therapies aligns with current trends in biotechnology, potentially offering a diverse pipeline. The recent IND submission to the FDA, coupled with the Australian HREC approval, indicates a well-coordinated global development plan.

Investors should note that while this news is promising, Phase 1 trials are early-stage and success is not guaranteed. However, the potential market for an effective SLE treatment is substantial. If CLN-978 demonstrates efficacy and safety, it could significantly boost Cullinan's market position and valuation. The company's Nasdaq listing (CGEM) provides liquidity for investors, but as with all biotech investments, risk management is important given the long and uncertain drug development process.

Phase 1 clinical trial is designed to assess the safety, pharmacokinetics and initial clinical activity of CLN-978 for patients with systemic lupus erythematosus

The trial will be conducted in multiple sites in Australia as well as other countries around the world

CAMBRIDGE, Mass., Sept. 17, 2024 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (Nasdaq: CGEM), a biopharmaceutical company focused on developing modality-agnostic targeted therapies, today received Human Research Ethics Committee (HREC) approval in Australia to initiate its global Phase 1 clinical trial to evaluate CLN-978, its CD19xCD3 bispecific T cell engager, for the treatment of systemic lupus erythematosus (SLE).

SLE affects approximately 430,000 individuals globally.¹ Currently available treatments do not routinely induce treatment-free remission, with most patients requiring lifelong immune suppression to treat symptoms without modifying the course of disease. CLN-978 is a novel CD19 bispecific T cell engager designed to deliver T cell-directed potency with off-the-shelf access and convenient dosing.

“We are pleased to receive this first approval to initiate our global study of CLN-978 in SLE in Australia,” said Jeffrey Jones, MD, MBA, Chief Medical Officer, Cullinan Therapeutics. “We have been focused on rapidly executing our global clinical development strategy for autoimmune diseases, and today’s approval is an important step to treat patients around the world living with SLE. Our investigational candidate, CLN-978, combines the optimal target (CD19) and modality (T cell engager) for a highly differentiated, potentially best-in-class program​. We look forward to working with all our sites, investigators, and patients as we continue to expeditiously progress development of CLN-978 in Australia and beyond.”

On September 16, Cullinan Therapeutics announced the submission of an Investigational New Drug Application to the U.S. Food and Drug Administration for this study.

About CLN-978 
CLN-978 is a novel, highly potent, half-life extended CD19xCD3 bispecific T cell engager construct. CLN-978 potently triggers redirected lysis of CD19-expressing target cells in vitro and in vivo. CLN-978 is engineered to achieve very high affinity binding to CD19 to efficiently target B cells expressing very low CD19 levels. A human serum albumin (HSA)-binding domain increases the serum half-life of CLN-978 and, with subcutaneous delivery, permits more patient-friendly dosing and potentially reduced toxicity. CLN-978 contains two single-chain variable fragments, one binding with very high affinity to the CD19 target and the other binding to CD3 on T cells, and a single-domain antibody binding to HSA. CLN-978 was developed by an internal Cullinan team and is a wholly owned asset. CLN-978 has the potential to offer a convenient, off-the-shelf therapeutic option for patients with autoimmune diseases such as SLE and rheumatoid arthritis. 

About Systemic Lupus Erythematosus (SLE)
SLE is a chronic, heterogeneous autoimmune disease in which the immune system attacks a patient’s own tissues. The most common manifestations of SLE include skin rashes, arthritis, swelling in the feet, and around the eyes, extreme fatigue, and low fevers. Lupus nephritis (LN) is a kidney disease and the most common severe manifestation of SLE. Approximately 40% of patients with SLE develop LN, which has a 10-year 30% mortality rate. SLE is more prevalent in women, people of color, and women of childbearing age. SLE affects approximately 430,000 individuals globally.¹ Currently available treatments do not routinely induce treatment-free remission, and most patients require lifelong immune suppression that treats symptoms without modifying the course of disease. 

About Cullinan Therapeutics  
Cullinan Therapeutics, Inc. (Nasdaq: CGEM) is a biopharmaceutical company dedicated to creating new standards of care for patients. Cullinan has strategically built a diversified portfolio of clinical-stage assets that inhibit key drivers of disease or harness the immune system to eliminate diseased cells in both autoimmune diseases and cancer. Cullinan’s portfolio encompasses a wide range of modalities, each with the potential to be best and/or first in class. Anchored in a deep understanding of oncology, immunology, and translational medicine, we create differentiated ideas, identify the most appropriate targets, and select the optimal modality to develop transformative therapeutics across a wide variety of autoimmune and cancer indications. We push conventional boundaries from candidate selection to differentiated therapeutic, applying rigorous go/no go criteria at each stage of development to fast-track only the most promising molecules to the clinic and, ultimately, commercialization. With deep scientific expertise, our teams exercise creativity and urgency to deliver on our promise to bring new therapeutic solutions to patients. Learn more about Cullinan at https://cullinantherapeutics.com/, and follow us on LinkedIn and X. 

Forward Looking Statements  
This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to, express or implied statements regarding the company’s beliefs and expectations regarding: our preclinical and clinical developments plans and timelines, the clinical and therapeutic potential of our product candidates, the strategy of our product candidates, and our research and development activities. The words “believe,” “continue,” “could,” “estimate,” “expect,” “intends,” “may,” “plan,” “potential,” “project,” “pursue,” “will,” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words.

Any forward-looking statements in this press release are based on management's current expectations and beliefs of future events and are subject to known and unknown risks and uncertainties that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. These risks include, but are not limited to, the following: uncertainty regarding the timing and results of regulatory submissions, including the IND that we filed for CLN-978; the risk that any INDs or other global regulatory submissions we may file with the United States Food and Drug Administration or other global regulatory agencies are not cleared on our expected timelines, or at all; the success of our clinical trials and preclinical studies; the risks related to our ability to protect and maintain our intellectual property position; the risks related to manufacturing, supply, and distribution of our product candidates; the risk that any one or more of our product candidates, including those that are co-developed, will not be successfully developed and commercialized; the risk that the results of preclinical studies or clinical studies will not be predictive of future results in connection with future studies; and the success of any collaboration, partnership, license or similar agreements. These and other important risks and uncertainties discussed in our filings with the Securities and Exchange Commission, including under the caption “Risk Factors” in our most recent Annual Report on Form 10-K and subsequent filings with the SEC, could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. While we may elect to update such forward-looking statements at some point in the future, we disclaim any obligation to do so, even if subsequent events cause our views to change, except to the extent required by law. These forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date of this press release. Moreover, except as required by law, neither the company nor any other person assumes responsibility for the accuracy and completeness of the forward-looking statements included in this press release. Any forward-looking statement included in this press release speaks only as of the date on which it was made.

Contacts:  
Investors  
Nick Smith  
+1 401.241.3516  
Nsmith@cullinantx.com   
  
Media  
Rose Weldon   
+1 215.801.7644   
rweldon@cullinantx.com  

---------------------------------------

^[1] GlobalData estimates. Includes U.S., EU5 (United Kingdom, Germany, France, Spain, Italy), Japan, Australia.

FAQ

What is the purpose of Cullinan Therapeutics' Phase 1 clinical trial for CLN-978 (CGEM)?

The Phase 1 clinical trial aims to assess the safety, pharmacokinetics, and initial clinical activity of CLN-978 for patients with systemic lupus erythematosus (SLE).

Where will Cullinan Therapeutics (CGEM) conduct the Phase 1 clinical trial for CLN-978?

The trial will be conducted in multiple sites in Australia as well as other countries around the world.

What is CLN-978 designed to do for SLE patients?

CLN-978 is a novel CD19 bispecific T cell engager designed to deliver T cell-directed potency with off-the-shelf access and convenient dosing for SLE patients.

How many people are affected by systemic lupus erythematosus (SLE) globally?

SLE affects approximately 430,000 individuals globally, according to the information provided in the press release.